Bausch + Lomb Corporation has announced the U.S. launch of the EyeGility Inserter, a preloaded intraocular lens (IOL) delivery system designed to enhance surgical efficiency and precision. The device is specifically engineered for the enVista family of IOLs, offering ophthalmologists a tool to streamline cataract procedures. This launch marks a significant expansion of the company's surgical portfolio, aiming to improve patient outcomes through advanced delivery technology.

The EyeGility Inserter is characterized by its balanced push force, which facilitates smooth delivery of the IOL into the eye. Additionally, the system supports convenient one-handed operation, allowing surgeons to maintain stability and control during the implantation process. These features are designed to address the need for reliability and ease of use in the operating room.

Product Availability and Rollout

The initial rollout of the EyeGility Inserter focuses on the enVista Aspire lens, which is available immediately. Bausch + Lomb has outlined a phased approach for the product's broader application, with availability for the enVista Envy lens scheduled for the coming months. This strategy ensures that the technology meets specific clinical requirements across different lens models within the enVista family.

Key Features of the EyeGility Inserter

The system's design prioritizes surgical performance and handling. Below is a summary of its primary attributes:

By introducing the EyeGility Inserter, Bausch + Lomb continues to innovate in the field of ophthalmic surgery, providing surgeons with tools that enhance procedural control and patient care.

Bausch + Lomb Corporation has discontinued the development of its BL1107 topical eye drop for glaucoma after the treatment failed to meet its primary endpoint in a Phase 2 study. The randomized, double-masked study enrolled 159 adults with primary open-angle glaucoma or ocular hypertension. It did not achieve the primary endpoint of change from baseline in visual field mean deviation at Day 28. Key secondary endpoints assessing visual function were also not achieved, though the study did show a reduction in intraocular pressure, indicating ocular target engagement. The safety profile remained consistent with prior clinical experience.

The company will now focus its resources on a sustained-release implant for geographic atrophy (GA), a vision-threatening disease, anticipating the start of clinical trials in 2028. This strategic pivot follows the acquisition of Whitecap Biosciences in 2025, which provided the technology platform for the implant. The company will continue collaborating with Ripple Therapeutics on the sustained-release implant. This technology platform allows drugs to be chemically engineered into controlled-release pharmaceuticals without polymers. Bausch + Lomb aims to develop the first small-molecule sustained-release implant specifically for GA, with multiple clinical and regulatory milestones expected over the coming years.

Pipeline Strategy

Bausch + Lomb's portfolio includes more than 60 assets under development. The company emphasizes a diversified pipeline strategy across Consumer, Pharmaceuticals, Surgical, and Vision Care segments to mitigate the risk inherent in drug development. Yehia Hashad, MD, executive vice president, R&D and chief medical officer, stated that success relies on a portfolio approach rather than single programs, allowing the company to make informed investment decisions based on clinical data.